Welcome to our dedicated page for ACCUSTEM SCIENCES news (Ticker: ACUT), a resource for investors and traders seeking the latest updates and insights on ACCUSTEM SCIENCES stock.
AccuStem Sciences, Inc. (OTCQB: ACUT) is a clinical-stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. The company's flagship product, StemPrintER, is a 20-gene prognostic assay designed to predict the risk of distant recurrence in cancer patients. This test measures the 'stemness' of tumors, indicating how likely a cancer is to recur or resist standard treatments, thus helping multi-disciplinary care teams manage patient care more effectively.
AccuStem has garnered attention for its innovative approach in cancer diagnostics. The company recently received a new patent from the US Patent and Trademark Office, further solidifying its intellectual property for the StemPrintER test. This test stratifies patients with early-stage breast cancer according to their recurrence risk, making it highly prognostic. Studies published in peer-reviewed journals have confirmed that patients with high 'stemness' are up to four times more likely to experience a distant recurrence compared to those with low 'stemness'.
Furthermore, AccuStem has been actively involved in various strategic partnerships to enhance the clinical utility and commercial viability of its products. For instance, a collaboration with the IEO in Milan has shown that StemPrintER outperforms the current market leader, OncotypeDX, in risk stratification for breast cancer recurrence. Additionally, the company is working closely with University Hospitals to further validate the clinical utility of StemPrintER beyond recurrence risk, potentially influencing surgical and radiological treatment plans.
AccuStem is also expanding its research and development efforts by partnering with EmeritusDX. This collaboration aims to validate StemPrintER for broader oncological applications, addressing unmet clinical needs across different cancer types. The company is optimistic about launching full commercialization in 2025, with projections indicating significant revenue growth and operational milestones.
With a robust pipeline and a series of strategic collaborations, AccuStem is well-positioned to revolutionize cancer diagnostics and improve patient outcomes. The company’s commitment to innovation and precision medicine marks it as a key player in the field of oncology diagnostics.
AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.
AccuStem Sciences (OTCQB: ACUT) announced that its Chairman, Gabriele Cerrone, has acquired an additional 24,500 shares, bringing his total ownership to 3,855,723 shares. This purchase reflects the Chairman's confidence in the company’s future, as AccuStem focuses on developing innovative molecular testing for cancer diagnostics aimed at improving patient outcomes. The company is dedicated to addressing critical clinical needs throughout cancer screening, treatment, and monitoring.
AccuStem Sciences, Inc. (OTCQB: ACUT) announced the appointment of Sean McDonald to its Board of Directors, increasing the board to five members. McDonald brings extensive experience in building healthcare organizations and securing funding for early-stage companies. Currently the CEO of Ocugenix, he previously held leadership roles at Precision Therapeutics and Automated Healthcare. His background will support AccuStem's mission to innovate cancer diagnostics through genomic testing. CEO Wendy Blosser expressed confidence in McDonald's ability to advance the company's growth strategy.
AccuStem Sciences (OTCQB: ACUT) announced the adjournment of its 2022 annual stockholders' meeting due to a lack of quorum. Originally scheduled for October 10, 2022, the meeting has been rescheduled for October 14, 2022. Proxies from stockholders represent approximately 36% of the outstanding shares. The company aims to solicit additional votes during this period. Stockholders of record as of September 14, 2022, are encouraged to vote by October 13, 2022. AccuStem focuses on enhancing cancer patient outcomes through proprietary molecular testing.
FAQ
What is the current stock price of ACCUSTEM SCIENCES (ACUT)?
What is the market cap of ACCUSTEM SCIENCES (ACUT)?
What is AccuStem Sciences, Inc.?
What is the StemPrintER test?
How does StemPrintER differ from other tests like OncotypeDX?
What recent achievements has AccuStem accomplished?
What are the future plans for AccuStem?
Who are AccuStem's strategic partners?
How is AccuStem addressing unmet clinical needs?
What is the significance of the recent patent granted to AccuStem?
What is AccuStem's approach to cancer diagnostics?
Where can I find more information about AccuStem?
